Jefferies initiated coverage of Disc Medicine (IRON) with a Buy rating and $89 price target Disc Medicine is a clinical stage biotech focused on hematological diseases, the analyst tells investors in a research note. The firm says the company is building a “unique portfolio” of non-malignant hematological disorders with the near-term driver being bitopertin in erythropoietic porphyrias, followed by two earlier assets that could generate greater potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRON:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
